Nanomedicine: how tiny carriers are learning to deliver drugs where they're needed

One of the oldest problems in medicine is not finding a drug that works, but getting it to the right place. A pill or injection usually spreads a drug through the whole body, so only a fraction reaches the diseased tissue — and the rest can cause side effects. Nanomedicine is the effort to fix that by packaging drugs into carriers built at the scale of a few tens of nanometres.

The core idea

A nanomedicine carrier is a particle far smaller than a human cell — often 10 to 200 nanometres across. Its job is to hold a drug and release it in the right place, at the right time.

Several designs are already in use or in trials:

• Liposomes. Tiny bubbles of the same fatty molecules that make up cell membranes, wrapping a drug inside. Some cancer chemotherapies already use them to reduce toxicity.
• Lipid nanoparticles. Fatty spheres that protect and carry fragile genetic material. These delivered the mRNA in COVID-19 vaccines.
• Polymer nanoparticles. Carriers made of biodegradable plastics that can release a drug slowly over time.

Why go this small

• Fewer side effects. By concentrating a drug where it is needed, nanocarriers can reduce the dose that reaches healthy tissue.
• Protecting fragile drugs. Molecules like mRNA fall apart quickly in the body; a nanoparticle shell shields them until delivery.
• Crossing barriers. The right size and surface can help a carrier slip through biological barriers that block ordinary drugs.
• Controlled release. Some carriers are designed to release their payload gradually, or only in response to a specific trigger such as acidity.

The mRNA vaccine proof point

The clearest demonstration came during the COVID-19 pandemic. The mRNA in those vaccines is extremely delicate and would be destroyed almost instantly on its own. Wrapping it in a lipid nanoparticle allowed it to reach cells intact — making the vaccines possible. It was, in effect, the largest real-world deployment of a nanomedicine to date.

The honest limits

Nanomedicine is not magic. Getting carriers to actually target only diseased cells — rather than just accumulating passively — remains genuinely hard, and many promising results in animals do not translate to humans. Manufacturing nanoparticles consistently and affordably at large scale is its own challenge, and long-term safety must be studied carrier by carrier.

Nanomedicine reframes an old question: not just "does this drug work?" but "can we deliver it precisely enough to matter?" The COVID vaccines showed the payoff when the answer is yes.

Why it matters for India

With a large population, a strong generic-pharmaceutical industry and growing biotech research, India has both the need and the capacity to work on affordable drug-delivery nanotechnology. For students, nanomedicine is a compelling meeting point of chemistry, biology and engineering — and a reminder that a breakthrough drug is only as useful as the system that delivers it.

Frequently asked questions

What is nanomedicine?

Nanomedicine is the use of extremely small carriers — typically tens of nanometres wide, such as liposomes and lipid nanoparticles — to deliver drugs more precisely, protect fragile molecules and reduce side effects compared with conventional dosing.

How does targeted drug delivery reduce side effects?

By concentrating a drug in or near the diseased tissue, a nanocarrier lowers the amount that circulates to healthy parts of the body, which can reduce toxicity and let lower total doses be used.

Are the mRNA COVID-19 vaccines a form of nanomedicine?

Yes. The mRNA in those vaccines is wrapped in lipid nanoparticles that protect it and carry it into cells. This is widely regarded as the largest real-world use of a nanomedicine delivery system so far.